Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
December 2020
-
Media ReleaseNovartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trialAt 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase…
-
Media ReleaseNovartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomasInterim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83%1…
-
Media ReleaseNovartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHDResults of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms1Chronic graft-versus-host disease (GvHD) is a life-threatening…
-
Featured NewsThe Co-Creating Impact Summit for the society and the planet
The Co-Creating Impact Summit happening on December 9th, 2020, will gather experts inside and outside of Novartis to continue our work of improving our impact on the society and the planet.
-
Featured NewsWhy healthcare’s digital moment is now
Novartis Chief Digital Officer, Bertrand Bodson, and Microsoft Corporate Vice President Research & Incubation, Peter Lee, discussed why healthcare’s digital moment is now.
-
In The NewsMoving towards the next normalHow changes driven by COVID-19 may shape pharma manufacturing in the long term.
November 2020
-
In The NewsEnabling a stable supply of medicines during COVID-19What are the key factors ensuring Novartis supply chains remain operational during the pandemic?
-
Featured NewsMeet Novartis Management 2020Annual meeting highlights progress on the company’s transformation and growth strategy.
-
Key ReleaseNovartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor eventNovartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies Key growth…
-
New hope for treating inflammatory diseases of the kidney
Novartis researchers aim to preserve kidney function – and quality of life – for patients.
-
Media ReleaseNovartis secures exclusive rights for potential acute respiratory distress syndrome cell therapyNovartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other…
-
Media ReleaseNew data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseasesPivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs. bosutinib in CML patients previously treated with two or more TKIsELARA results for Kymriah® in relapsed or…
Pagination
- ‹ Previous page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- …
- 152
- › Next page